Virus therapy for melanoma with brain tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a virus therapy (oncolytic adenovirus) injected directly into melanoma tumors, including those in the brain. It aims to see if the virus can safely shrink tumors and improve the immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have stage IV melanoma that has spread (including to the brain for some groups)
- You must be able to have an MRI of the brain with contrast
- You must be generally active and able to care for yourself (ECOG score 0 or 1)
- You must be taking an immunotherapy drug (like ipilimumab, nivolumab, or pembrolizumab) if you are in certain groups
- You must have normal blood, liver, and kidney function test results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.